Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Pro Pharma Communications International. EMA recommends approval of etanercept biosimilar. GaBI Online. 2015 Nov 27.
2. Pro Pharma Communications International. Amgen submits biosimilar adalimumab application to FDA. GaBI Online. 2015 Nov 27.
3. O’Dell JR, Rohr M, Cohen SB, Thorne JC, Mikuls TR. Underuse of methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) in the United States (US): Results of a comprehensive pharmaceutical claims analysis. Arthritis Rheumatol. 2015;67(suppl 10).
4. Strand V, Kosinski M, Graham N, et al. Impact of sarilumab on fatigue, pain, morning stiffness, productivity and health related quality of life (HRQoL) in patients with active rheumatoid arthritis who were inadequate responders or intolerant of anti-TNF-α therapy: Results from a phase 3 study (RCT). Arthritis Rheumatol. 2015;67(suppl 10).
5. Pfizer Inc. News release: Pfizer’s Lyrica fails Phase III study in post-traumatic neuropathic pain. First Word Pharma. 2015 Nov 25.
6. University of Warwick. News release: Researchers create world’s first ibuprofen patch—delivering pain relief directly through skin. 2015 Dec 8.